All In Biotech

Drug Trial Radar · NCT06465303

A Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)

An Exploratory, Randomised, Double-blind, Multicentre, Placebo-controlled Study of RTP-026 to Assess Safety, Tolerability and Efficacy in Patients With ST-Elevation Myocardial Infarction (STEMI)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Jul 16, 2024

Primary completion

Jul 2, 2026

Study completion Jul 2, 2026

Sponsor

Lead sponsor
ResoTher PharmaIndustry
Sponsor type
Industry
First posted
Jun 18, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an exploratory, randomized, double-blind, multicentre, placebo-controlled study of RTP-026. The study population will consist of men and women with documented evidence of ST-elevation myocardial infarction (STEMI) referred to primary Percutaneous Coronary Intervention (PCI).

Conditions

  • ST Elevation Myocardial Infarction

Interventions

  • RTP-026Drug

    Intervention is for each subject administered as three 30-minutes infusions of either A: 25μg/kg RTP-026; or B: ≥ 26μg/kg and ≤75μg/kg RTP-026; or C: A maximum of 3 x treatment dose RTP-026 as given in B;

  • PlaceboDrug

    Intervention is for each subject administered as three 30-minutes infusions of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Cardiac Troponin T (cTNT)Time frame: 24 hours
  2. Change in Creatinine kinase-MB (CK-MB)Time frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hjertecenteret, Rigshospitalet

    Copenhagen, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.